Liver fat content measured by imaging: molecular mechanisms & dependencies

How nutrients influence it

Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.

Human evidence only

How nutrients reach it in more than one step

Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.

Tracing routes…

What it does

Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.

Recorded relationships

What acts on it

CGA did not outperform placebo for the measured hepatic-fat endpoint.
Chlorogenic acid / 5-O-caffeoylquinic acid → Liver fat content measured by imaging source_derived_draftungraded
Experimental context and source evidence
evidence_span
{"source_cache": "artifacts/chlorogenic_acid-research/33838673.abstract.txt", "locator": "Primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "749cbe05e73aeb9c4a69c8c00e8a3839241f343b5c0eb9662b64f4127506f319", "start_char": 0, "end_char": 2205, "text_sha256": "749cbe05e73aeb9c4a69c8c00e8a3839241f343b5c0eb9662b64f4127506f319"}
experimental_model
Six-month double-blind randomized four-arm trial
exposure
Daily 200 mg CGA, 200 mg caffeine, both, or starch placebo
limitations
Chronic human liver disease differs from surgical mouse regeneration. The trial does not isolate all possible formulations, but its null hepatic result must remain visible.
nutrient_topic
Chlorogenic acid research collection; topical membership is not evidence of a direct dietary effect. · Chlorogenic acid / 5-O-caffeoylquinic acid
organism
Human participants with type 2 diabetes and NAFLD
plain_language
The mechanistic promise did not translate into this clinical liver outcome.
primary_references
[chlorogenic_acid-p33838673] Effects of supplementation with main coffee components including caffeine and/or chlorogenic acid on hepatic, metabolic, and inflammatory indices in patients with non-alcoholic fatty liver disease and type 2 diabetes: a randomized, double-blind, placebo-controlled, clinical trial. (2021). https://pubmed.ncbi.nlm.nih.gov/33838673/ DOI: 10.1186/s12937-021-00694-5
tissue_or_cell_type
FibroScan, hepatic blood tests, metabolic and inflammatory markers
Chlorogenic acid: metabolism, signaling and nutrient connections (2026-09-17) · lines 1036–1047
AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Six-month double-blind randomized four-arm trial · source_derived_draft · unverified_draft
### chlorogenic_acid-liver-fat-null CGA did not outperform placebo for the measured hepatic-fat endpoint. Condition category: normal nutrient_topic: Chlorogenic acid research collection; topical membership is not evidence of a direct dietary effect. plain_language: The mechanistic promise did not translate into this clinical liver outcome. organism: Human participants with type 2 diabetes and NAFLD tissue_or_cell_type: FibroScan, hepatic blood tests, metabolic and inflammatory markers experimental_model: Six-month double-blind randomized four-arm trial limitations: Chronic human liver disease differs from surgical mouse regeneration. The trial does not isolate all possible formulations, but its null hepatic result must remain visible. exposure: Daily 200 mg CGA, 200 mg caffeine, both, or starch placebo evidence_span: {"source_cache": "artifacts/chlorogenic_acid-research/33838673.abstract.txt", "locator": "Primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "749cbe05e73aeb9c4a69c8c00e8a3839241f343b5c0eb9662b64f4127506f319", "start_char": 0, "end_char": 2205, "text_sha256": "749cbe05e73aeb9c4a69c8c00e8a3839241f343b5c0eb9662b64f4127506f319"} [chlorogenic_acid-p33838673] Effects of supplementation with main coffee components including caffeine and/or chlorogenic acid on hepatic, metabolic, and inflammatory indices in patients with non-alcoholic fatty liver disease and type 2 diabetes: a randomized, double-blind, placebo-controlled, clinical trial. (2021). https://pubmed.ncbi.nlm.nih.gov/33838673/ DOI: 10.1186/s12937-021-00694-5
Complete structured claim and evidence
Berberine did not reduce liver fat versus placebo; the between-group estimate was 0.9 percentage points with 97.5% CI -0.4 to 2.1.
Berberine → Liver fat content measured by imaging source_derived_draftungraded
Experimental context and source evidence
evidence_span
{"source_cache": "artifacts/berberine-research/41543854.abstract.txt", "locator": "Primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "1093df47a715746d0334d7d7f3c9c0c71e502b43b47b383b21900b982d6ad021", "start_char": 0, "end_char": 2354, "text_sha256": "1093df47a715746d0334d7d7f3c9c0c71e502b43b47b383b21900b982d6ad021"}
experimental_model
Multicenter double-blind randomized placebo-controlled trial
exposure
Berberine 1 g/day for six months
limitations
No significant primary fat-reduction effect. Lipid endpoints were secondary; this population differs from diabetes trials and does not resolve every liver-disease subgroup.
nutrient_topic
Berberine research collection; topical membership is not evidence of a direct dietary effect. · Berberine
organism
337 diabetes-free adults with obesity and MASLD in China
plain_language
A plausible metabolic mechanism did not produce this primary clinical outcome.
primary_references
[berberine-p41543854] Berberine and Adiposity in Diabetes-Free Individuals With Obesity and MASLD: A Randomized Clinical Trial. (2026). https://pubmed.ncbi.nlm.nih.gov/41543854/ DOI: 10.1001/jamanetworkopen.2025.54152
tissue_or_cell_type
CT visceral adipose area and liver fat; lipid endpoints
Berberine: metabolism, nutrient connections and drug interactions (2026-09-17) · lines 1260–1271
AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Multicenter double-blind randomized placebo-controlled trial · source_derived_draft · unverified_draft
### berberine-masld-liver-null Berberine did not reduce liver fat versus placebo; the between-group estimate was 0.9 percentage points with 97.5% CI -0.4 to 2.1. Condition category: normal nutrient_topic: Berberine research collection; topical membership is not evidence of a direct dietary effect. plain_language: A plausible metabolic mechanism did not produce this primary clinical outcome. organism: 337 diabetes-free adults with obesity and MASLD in China tissue_or_cell_type: CT visceral adipose area and liver fat; lipid endpoints experimental_model: Multicenter double-blind randomized placebo-controlled trial limitations: No significant primary fat-reduction effect. Lipid endpoints were secondary; this population differs from diabetes trials and does not resolve every liver-disease subgroup. exposure: Berberine 1 g/day for six months evidence_span: {"source_cache": "artifacts/berberine-research/41543854.abstract.txt", "locator": "Primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "1093df47a715746d0334d7d7f3c9c0c71e502b43b47b383b21900b982d6ad021", "start_char": 0, "end_char": 2354, "text_sha256": "1093df47a715746d0334d7d7f3c9c0c71e502b43b47b383b21900b982d6ad021"} [berberine-p41543854] Berberine and Adiposity in Diabetes-Free Individuals With Obesity and MASLD: A Randomized Clinical Trial. (2026). https://pubmed.ncbi.nlm.nih.gov/41543854/ DOI: 10.1001/jamanetworkopen.2025.54152
Complete structured claim and evidence

The events it takes part in

A mechanism often involves more than two components. These are the full events, with every participant and its role.

Situations it appears in

Low-supply and faulty-machinery situations recorded in the chapters where this component plays a part.

In the sources

Preserved passages that mention this component, quoted exactly. Open one to read it in context.

Open hypotheses

Proposed ideas that involve this component. They are labeled as hypotheses and do not change any recorded statement.

This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.

Liver fat content measured by imaging